Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : HOT STOCKS 100% 200% 300% profits possible short term -- Ignore unavailable to you. Want to Upgrade?

To: Jay1 who wrote (1108)	8/4/1998 11:00:00 AM
From: WTT2	Read Replies (1) \| Respond to of 2038

<<DYGN>> receiving more positive news today.. CAMBRIDGE, Mass.--(BW HealthWire)--Aug. 4, 1998--DynaGen, Inc. (NASDAQ:DYGN) (BSE:DYG) today announced that through a restructuring with Superior Pharmaceutical Shareholders, it has reduced the acquisition purchase price by $5.0 million. Specifically, this agreement eliminates the $5.0 million common stock payment by DynaGen which was due in June 1998. DynaGen is currently in negotiations with several financial institutions to obtain conventional bank financing which will be used to retire the remaining note obligation to the Superior Shareholders. Dynagen, Inc. is a health care company involved in the research, development, manufacture and distribution of brand and generic therapeutic products. DynaGen's subsidiary, Able Laboratories, Inc. develops and manufactures the company's generic products in its FDA registered 46,000 square foot facility located in S. Plainfield, NJ. The company markets and distributes products to independent retail chain and institutional pharmacies through its wholly-owned marketing subsidiaries, Superior Pharmaceutical Company and Generic Distributors Incorporated. The Company maintains operations in Massachusetts, New Jersey, Ohio and Louisiana.